AbbVie (ABBV), a prominent force in the pharmaceutical industry, has charted a dynamic course in the stock market over the years. The table below outlines AbbVie’s annual stock performance, reflecting a trajectory characterized by notable gains and some challenges. This summary illustrates AbbVie’s resilience in facing market volatility, underscoring its commitment to advancing medical innovations and healthcare solutions for patients worldwide.
Annual Returns of AbbVie Stock (ABBV)
| Year | Beginning | Ending | Gain/Loss | S&P 500 |
|---|---|---|---|---|
| 2023 | $162.38 | $154.97 | -4.56% | 24.73% |
| 2022 | $135.42 | $161.61 | 19.34% | -19.95% |
| 2021 | $105.41 | $135.40 | 28.45% | 28.79% |
| 2020 | $89.55 | $107.15 | 19.65% | 15.29% |
| 2019 | $89.23 | $88.54 | -0.77% | 28.71% |
| 2018 | $98.41 | $92.19 | -6.32% | -7.01% |
| 2017 | $62.41 | $96.71 | 54.96% | 18.42% |
| 2016 | $57.61 | $62.62 | 8.70% | 11.24% |
| 2015 | $65.89 | $59.24 | -10.09% | -0.69% |
| 2014 | $51.98 | $65.44 | 25.89% | 12.39% |
| 2013 | $35.12 | $52.81 | 50.37% | 26.39% |
The table above displays the ABBV Yearly Return Rate, highlighting AbbVie’s annual stock performance on a split-adjusted basis. This data does not include dividends, stock spin-offs, taxes, or transaction commissions.
AbbVie (ABBV) Stock History
The Early Years (2013-2015)
AbbVie’s journey in the stock market commenced with its spin-off from Abbott Laboratories and its subsequent Initial Public Offering (IPO) in 2013. Starting its independent journey with a significant surge of 50.37% in its first year, AbbVie quickly established itself as a formidable entity in the pharmaceutical sector.
The following year, 2014, saw the company’s stock continue to rise by 25.89%, reinforcing investor confidence and highlighting its potential for growth and innovation. However, 2015 presented the first major challenge, with a -10.09% decline, emphasizing the unpredictable nature of the stock market and the inherent challenges of sustaining growth.
A Period of Recovery and Growth (2016-2018)
After the dip in 2015, AbbVie rebounded in 2016 with an 8.70% increase in its stock value, initiating a period of recovery and positive growth. The upward trend persisted into 2017, showcasing an exceptional gain of 54.96%, the highest in the company’s history up to that point.
This growth was attributed to successful product launches and strong market performance. However, 2018 marked another challenging year with a -6.32% decrease, reminding stakeholders of the unpredictable market dynamics.
A Rollercoaster of Successes and Setbacks (2019-2023)
The following years were a mix of successes and setbacks for AbbVie. In 2019, the company experienced a slight decline of -0.77%, a minor hiccup in its otherwise upward trajectory.
The stock rebounded strongly in 2020 and 2021, with gains of 19.65% and 28.45% respectively, driven by strategic acquisitions and a diversified product portfolio that bolstered its market position.
However, 2022 saw a significant achievement with a 19.34% increase, defying broader market trends which were generally negative. Despite these successes, 2023 brought a -4.56% loss, amidst a positive year where the S&P 500 surged by 24.73%, highlighting the complexities of market forces and the impact on even the most stable stocks.